<DOC>
	<DOCNO>NCT01859689</DOCNO>
	<brief_summary>This phase II trial study well internal radiation therapy work treat patient low-risk prostate cancer . Internal radiation use radioactive material place directly near tumor kill tumor cell .</brief_summary>
	<brief_title>Internal Radiation Therapy Treating Patients With Low-Risk Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine long term 5 year prostate specific cancer ( PSA ) biochemical control use Phoenix definition PSA nadir + 2 target hemi-gland brachytherapy . SECONDARY OBJECTIVES : I . To assess acute late toxicity outcomes follow target brachytherapy accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v4.0 . II . To determine change baseline health-related quality life indicator use validate Expanded Prostate Cancer Index Composite ( EPIC ) questionnaire , International Index Erectile Function ( IIEF ) questionnaire , International Prostate Symptom Score ( IPSS ) questionnaire . III . To assess potential value multiparametric magnetic resonance imaging , include dynamic contrast enhancement perfusion image diffusion tensor neurovascular tactographic image predict development equivocal disease ( ED ) follow radiation treatment . OUTLINE : Patients undergo 3 fraction image-guided high-dose rate ( HDR ) brachytherapy 2 day . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Histologically confirm primary nonmetastatic adenocarcinoma prostate Unilateral prostate cancer determine prostate biopsy Less equal 3 positive biopsy core No biopsy core &gt; = 50 % positive cancer Karnofsky performance status ( KPS ) &gt; = 70 At least 12 core prostate biopsy ; perform repeat University California Los Angeles ( UCLA ) Artemis guide biopsy suspicious target lesion identify multiparametric ( mp ) magnetic resonance imaging ( MRI ) Clinical stage T1c T2a PSA &lt; 10 ng/ml Gleason score 3+3=6 Patients previously receive radiation therapy pelvis Refusal sign inform consent Patients participate concurrent treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>